Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments

Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments

Prostate cancer (PC) is the second most common cancer in men worldwide. Despite recent advances in diagnosis and treatment, castration-resistant prostate cancer (CRPC) remains a significant medical challenge. Prostate cancer cells can develop mechanisms to resist androgen deprivation therapy, such a...

Full description

Bibliographic Details
Main Authors: Thi Khanh Le, Quang Hieu Duong, Virginie Baylot, Christelle Fargette, Michael Baboudjian, Laurence Colleaux, David Taïeb, Palma Rocchi
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Cancers
Subjects:
androgen signaling
castration-resistant prostate cancer
androgen deprivation therapy (ADT)
chemotherapy
immunotherapy
PARP inhibitors
Online Access:https://www.mdpi.com/2072-6694/15/20/5047

Internet

https://www.mdpi.com/2072-6694/15/20/5047

Similar Items